Why Is IMMUNOVANT INC (IMVT) Stock Moving Today?

IMVT stock is down 7.51% at $34.49 as of the latest trade, marking a sharp decline driven by the announcement that its IMVT-1402 lupus study failed to meet its primary endpoint. The company has decided to discontinue development of the drug in cutaneous lupus, though it will continue to explore the therapy for other autoimmune conditions. The stock opened with a -2.9% gap and has since traded lower, reaching a session low of $32.00 before settling near $34.50.

What Happened

Immunovant announced that its 57-patient proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosus did not achieve statistical significance on the primary CLASI-A percent-change endpoint at Week 12. This outcome prompted the company to halt further development of the drug in the indication. The decision has led to a sharp selloff, with the stock falling to over 3-month lows. The move has also drawn attention from market participants, with several news outlets highlighting the trial setback as a key factor behind the stock’s performance.

What The Data Shows

The stock opened at $36.20 and has traded in a wide range, reaching a high of $37.00 and a low of $32.00. Volume has reached 0.8 million shares, which is 0.5 times the 3-month daily average. Over the last 8 sessions, the stock has declined by 5.0% from $38.90 to $36.95. Additionally, the 52-week tape shows 22 fresh 52-week lows and one 52-week high on September 23. Recent insider transactions include 14 sales totaling $4.4 million in the last 90 days, with the most recent sale occurring on August 28.

What To Watch

Investors should monitor Immunovant’s Q1 2027 earnings call, scheduled for later in the year, as well as the broader coverage and sentiment shifts in the coming weeks.